Oncotelic lowers CEO milestone threshold from $100M to $45M market cap for stock vesting

Oncotelic Therapeutics, Inc.

Amendment reduces first market cap milestone for CEO Vuong Trieu's restricted stock from $100M to $45M.
Similar amendment with Jefferson Capital Ventures LLC lowers its milestone threshold to $45M.
Company states changes are to support progress including equity line with Mast Hills and uplisting efforts.
Other terms and milestones of the restricted stock agreements remain unchanged.
CEO's preferred stock award is tied to the same reduced milestone; no dilution details provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.